RecruitingNCT06989190

The MIND Study - Microangiopathy IN Diabetes

Sponsor

HJN Sverige AB/Neko Health

Enrollment

400 participants

Start Date

Dec 19, 2023

Study Type

OBSERVATIONAL

Conditions

Diabetes Type 1

Summary

This clinical investigation will evaluate two contactless optical devices based on spatial frequency domain and laser speckle technology for quantification of the skin micro-circulation in patients with diabetes mellitus type 1.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating the relationship between Type 1 diabetes and small blood vessel damage (microangiopathy) — including effects on the eyes, kidneys, and nerves — across different levels of severity, from no complications to severe diabetic complications. **You may be eligible if...** - You have Type 1 diabetes - You are 18–45 years old (or up to 60 if not enough younger participants are found) - For Phase 1: you have severe complications including proliferative retinopathy (eye damage), large amounts of protein in urine, significant kidney disease, and severe nerve damage with or without foot ulcers - For Phase 2: you have a range of complication levels, from none to moderate **You may NOT be eligible if...** - You have Type 2 diabetes - You are outside the age range - You do not meet the complication profile for the phase you are being considered for Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.